Teva’s Azilect Unlikely to See Additional Utility in Early Parkinson’s Based on Recent Trial Results

 Financial Times (FT.com)
April 2, 2013
Teva’s Azilect Unlikely to See Additional Utility in Early Parkinson’s Based on Recent Trial Results

Featurng: Dr. Andrew Feigin, investigator at the Feinstein Institute for Medical Research
 

Read this Story

Focus onHealth TV

Watch Focus onHealth, Northwell Health's TV show. It's the healthy way to stay informed!